Achiko reports an EBITDA loss of USD $1.9 million, compared to an EBITDA loss of USD $4.6 million for the six months ending June 30, 2021.Focal points of.
08.12.2021 Achiko s Commercialisation Update: Optimised second-generation Covid-19 diagnostic test receives full product registration approval in Indonesia | Achiko AG | News | Nachricht | Mitteilung
02.12.2021 - EQS Group-News: Achiko AG / Key word(s): Miscellaneous Achiko s position on Omicron variant 02.12.2021 / 06:45 Achiko s position on Omicron variant - The chemical mode of action of AptameX, Achiko s rapid Covid-19 test, strongly suggests that . Seite 1